CJC-1295 (no DAC) vs PDA
Both CJC-1295 (no DAC) and PDA are used for recovery. Here's how their evidence, dosing, and regulatory status actually compare.
CJC-1295 (no DAC)
Evidence BModified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
View full CJC-1295 (no DAC) profile →PDA
Evidence C+Pentadeca Arginate (PDA)
A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.
View full PDA profile →Side-by-Side
| Attribute | CJC-1295 (no DAC) | PDA |
|---|---|---|
| Evidence Grade | B | C+ |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — newer compounded analog of BPC-157 |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 200–500 mcg daily (subcutaneous) |
| Clinics Indexed | 156 | 41 |
| Categories | growth-hormone, anti-aging, recovery | recovery, anti-inflammatory |
Key reported benefits — CJC-1295 (no DAC)
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Key reported benefits — PDA
- ✓Tissue repair
- ✓Anti-inflammation
- ✓Potentially better stability than BPC-157
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.